Ranucci G, Page C, Marchionni E, Minotti C, Silvestrini G, Gastaldi S
Ann Hematol. 2024; 103(12):5999-6002.
PMID: 39672944
DOI: 10.1007/s00277-024-06140-w.
Blombery P, Pazhakh V, Albuquerque A, Maimaris J, Tu L, Briones Miranda B
EJHaem. 2023; 4(2):463-469.
PMID: 37206266
PMC: 10188477.
DOI: 10.1002/jha2.698.
Morris R, Zhang Y, Ellyard J, Vinuesa C, Murphy J, Laktyushin A
Nat Commun. 2021; 12(1):6110.
PMID: 34671038
PMC: 8528861.
DOI: 10.1038/s41467-021-26394-6.
Aguilera-Diaz A, Vazquez I, Ariceta B, Manu A, Blasco-Iturri Z, Palomino-Echeverria S
PLoS One. 2020; 15(1):e0227986.
PMID: 31978184
PMC: 6980571.
DOI: 10.1371/journal.pone.0227986.
Flores A, Argetsinger L, Stadler L, Malaga A, Vander P, DeSantis L
Diabetes. 2019; 68(11):2049-2062.
PMID: 31439647
PMC: 6804625.
DOI: 10.2337/db19-0608.
Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.
Plo I, Bellanne-Chantelot C, Mosca M, Mazzi S, Marty C, Vainchenker W
Front Endocrinol (Lausanne). 2017; 8:234.
PMID: 28955303
PMC: 5600916.
DOI: 10.3389/fendo.2017.00234.
The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
Maslah N, Cassinat B, Verger E, Kiladjian J, Velazquez L
Leukemia. 2017; 31(8):1661-1670.
PMID: 28484264
DOI: 10.1038/leu.2017.139.
Mutational analysis of SH2B3 in Korean patients with BCR-ABL1 negative myeloproliferative neoplasm.
Kim N, Kim I, Chang C, Lee E, Kim H, Song M
Ann Lab Med. 2015; 36(1):67-9.
PMID: 26522763
PMC: 4697347.
DOI: 10.3343/alm.2016.36.1.67.
The genomic landscape of juvenile myelomonocytic leukemia.
Stieglitz E, Taylor-Weiner A, Chang T, Gelston L, Wang Y, Mazor T
Nat Genet. 2015; 47(11):1326-1333.
PMID: 26457647
PMC: 4626387.
DOI: 10.1038/ng.3400.
LNK (SH2B3): paradoxical effects in ovarian cancer.
Ding L, Sun Q, Lin D, Chien W, Hattori N, Dong X
Oncogene. 2014; 34(11):1463-74.
PMID: 24704825
PMC: 4188804.
DOI: 10.1038/onc.2014.34.
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.
Gabler K, Behrmann I, Haan C
JAKSTAT. 2013; 2(3):e25025.
PMID: 24069563
PMC: 3772115.
DOI: 10.4161/jkst.25025.
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis.
Spolverini A, Pieri L, Guglielmelli P, Pancrazzi A, Fanelli T, Paoli C
Haematologica. 2013; 98(9):e101-2.
PMID: 23812944
PMC: 3762108.
DOI: 10.3324/haematol.2013.090175.
SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
Koren-Michowitz M, Gery S, Tabayashi T, Lin D, Alvarez R, Nagler A
Br J Haematol. 2013; 161(6):811-20.
PMID: 23590807
PMC: 3672250.
DOI: 10.1111/bjh.12327.
